Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03367910 · ClinicalTrials.gov registry record · Phase 1
Fecal Microbiota Transplantation (FMT) for MDRO UTI
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03367910: Completed Phase 1 study, sponsored by Washington University School of Medicine.
NCT03367910 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03367910, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and impact of fecal microbiota transplantation (FMT) on the fecal and urine microbiome, urine metabolome, risk of recurrent urinary tract infection (UTI), and persistent multidrug resistant organism (MDRO) colonization of patients with a history of recurrent MDRO UTIs. This is an open label phase 1-2 study.
Primary Outcome
The number, types, severity, and relation of adverse events to study procedures or product will be analyzed.
Interventions
- DRUG Fecal microbiota transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 1 |
What the finished NCT03367910 record still lists
NCT03367910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Fecal microbiota transplant is the first listed.
NCT03367910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03367910 about?
NCT03367910 is a clinical study titled "Fecal Microbiota Transplantation (FMT) for MDRO UTI". The purpose of this study is to determine the safety and impact of fecal microbiota transplantation (FMT) on the fecal and urine microbiome, urine metabolome, risk of recurrent urinary tract infection (UTI), and persistent multidrug resistant organism (MDRO) colonization of patients with a history o...
What is the current status of trial NCT03367910?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2018-02-08. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT03367910?
The interventions under investigation include: Fecal microbiota transplant (DRUG).
Who is sponsoring clinical trial NCT03367910?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03367910's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI